Grant ID | RP240537 |
Awarded On | February 19, 2025 |
Title | Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core |
Program | Academic Research |
Award Mechanism | Core Facility Support Awards |
Institution/Organization | Baylor Research Institute |
Principal Investigator/Program Director | Erxi Wu |
Cancer Sites | All Sites |
Contracted Amount |
$2,999,989* *Pending contract negotiation |
Lay Summary |
Many anticancer agents function by targeting specific molecules involved in the proliferation and survival of cancer cells, while sparing normal cells. However, the unknown binding targets or unintended off-targets of these drugs often result in less effective treatments and lower patient survival rates. This knowledge gap also hinders the advancement of more efficacious cancer therapies. In response to this challenge, Dr. Wu's team has innovated in identifying the binding targets of anticancer drugs, facilitating a deeper understanding of their mechanisms. Moreover, they have formulated cost-effective, safe methodologies for screening aptamer-based therapeutics for cancer treatment. To sup... |